These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8843294)

  • 1. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.
    Kashuba AD; Ballow CH; Forrest A
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.
    Vinks AA; Mouton JW; Touw DJ; Heijerman HG; Danhof M; Bakker W
    Antimicrob Agents Chemother; 1996 May; 40(5):1091-7. PubMed ID: 8723446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
    Forrest A; Ballow CH; Nix DE; Birmingham MC; Schentag JJ
    Antimicrob Agents Chemother; 1993 May; 37(5):1065-72. PubMed ID: 8517693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.
    Traunmüller F; Schenk P; Mittermeyer C; Thalhammer-Scherrer R; Ratheiser K; Thalhammer F
    J Antimicrob Chemother; 2002 Jan; 49(1):129-34. PubMed ID: 11751776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokinetics.
    Amsden GW; Ballow CH
    Pharmacotherapy; 1996; 16(5):937-41. PubMed ID: 8888090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of optimal sampling strategy and adaptive study design.
    Drusano GL; Forrest A; Snyder MJ; Reed MD; Blumer JL
    Clin Pharmacol Ther; 1988 Aug; 44(2):232-8. PubMed ID: 3293877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.
    Yuen GJ; Drusano GL; Forrest A; Plaisance K; Caplan ES
    Clin Pharmacol Ther; 1989 Oct; 46(4):451-7. PubMed ID: 2791447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
    Highet VS; Forrest A; Ballow CH; Schentag JJ
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections.
    Buijk SL; Gyssens IC; Mouton JW; Van Vliet A; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2002 Jan; 49(1):121-8. PubMed ID: 11751775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftazidime in normal and uremic subjects.
    Leroy A; Leguy F; Borsa F; Spencer GR; Fillastre JP; Humbert G
    Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent bolus dosing of ceftazidime in critically ill patients.
    Young RJ; Lipman J; Gin T; Gomersall CD; Joynt GM; Oh TE
    J Antimicrob Chemother; 1997 Aug; 40(2):269-73. PubMed ID: 9301994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
    Paulfeuerborn W; Müller HJ; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1835-41. PubMed ID: 8239592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.